Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?
Chronic hand eczema is now considered a “common” skin disease in the United States, according to results from the CHECK study ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Raj Chovatiya, MD, PhD, MSCI, explains how addressing the most burdensome components of chronic hand eczema can improve ...
Medpage Today on MSN
Regulatory T-Cell Drug Promising for Eczema, With Hint for Asthma as Well
For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...
Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback